Drug Trial Radar · NCT04363164
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 19, 2020
Primary completion
Jul 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense
- First posted
- Apr 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Conditions
- Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionateDrug
Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
EnzalutamideDrug
Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
Testosterone enanthateDrug
Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical or Radiographic Progression free survivalTime frame: Up to 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Diego (UCSD)
San Diego, California · Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Dana-Faber Cancer Institute
Boston, Massachusetts · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.